← Back to Search
Design And Synthesis Of Dual-ligand Modified Chitosan As A Liver Targeting Vector
Houxiang Chen, Min Li, T. Wan, Qichang Zheng, Mingrong Cheng, Shi-qi Huang, Y. Wang
Published 2011 · Materials Science, Medicine
Download PDFAnalyze on Scholarcy
Vector plays an important role in hepatic targeted drug delivery system. In this study, a novel material as a liver targeting vector, dual-ligand modified chitosan (GCGA) composed of chitosan (CTS), glycyrrhetinic acid (GA) and lactobionic acid (LA), was designed and synthesized by an orthogonal experiment with two-step synthesis under mild conditions. The synthesized final product was characterized and confirmed by FTIR and 1H-NMR spectroscopy, and DS of GA and LA in CTS were measured to be 13.77 and 16.74 mol% using 1H-NMR, respectively. The cytotoxicity of CTS and GCGA was concentration dependent which was inverse proportion to the cell viability by MTT assay using L929 cell line, and inhibitory concentration 50% (IC50) was 0.2 mg/ml for GCGA. The in vitro targeting efficiency and the in vitro cellular uptake were investigated. Compared with CTS NPs and GA-CTS NPs, GCGA NPs showed good cell specificity to BEL-7402 cells via the dual-ligand-receptor-mediated recognition, leading to a higher affinity to BEL-7402 cells. The results suggested that GCGA described here has the potential to be used as an effective vector for hepatic targeted drug therapy.
This paper references
Pharmacological aspects of targeting cancer gene therapy to endothelial cells.
H. Sedlacek (2001)
Significance of the expression of glutameta decarboxylase 65 and protein kinase C in primary hepatocarcinoma tissues
Miao Xong-ying (2003)
Physical and chemical stability of drug nanoparticles.
L. Wu (2011)
Hepatic Binding Protein: The Galactose‐Specific Receptor of Mammalian Hepatocytes
R. Stockert (1983)
Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte.
A. Schwartz (1980)
Liver gene therapy: advances and hurdles
T. Nguyen (2004)
Chitosan based oligoamine polymers: synthesis, characterization, and gene delivery.
B. Lu (2009)
Arabinogalactan for hepatic drug delivery.
E. Groman (1994)
Preparation, characterization, and drug release in vitro of chitosan-glycyrrhetic acid nanoparticles.
Y. Zheng (2006)
MOLECULAR NUCLEAR IMAGING FOR TARGETING AND TRAFFICKING
H. Bom (2006)
Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Q. Tian (2010)
Uptake of glycyrrhizin by isolated rat hepatocytes.
S. Ishida (1993)
Recent advances on chitosan-based micro- and nanoparticles in drug delivery.
S. Agnihotri (2004)
Natural and artificial chitosan-inorganic composites.
C. Muzzarelli (2002)
Carbohydrate-specific receptors of the liver.
G. Ashwell (1982)
Recent advancement in Chitosan based formulations and itspharmaceutical application
S. Kalyan (2010)
Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference.
J. Dufour (2010)
Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid.
C. O'brian (1990)
Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting.
Qin Tian (2010)
Specific binding of glycyrrhetinic acid to the rat liver membrane.
M. Negishi (1991)
: advances and hurdles
Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo.
Mingrong Cheng (2011)
Galactosyl conjugated N-succinyl-chitosan-graft-polyethylenimine for targeting gene transfer.
B. Lu (2010)
Structural features and bioactivities of the chitosan.
G. Chen (2011)
Natural and artificial chitosaninorganic composites
C. Muzzarelli (2002)
Targeted gene delivery to selected liver segments via isolated hepatic perfusion.
Hiroyasu Kinoshita (2010)
Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes
J. Baenziger (1980)
Synthesis of a novel glycoconjugated chitosan and preparation of its derived nanoparticles for targeting HepG2 cells.
F. Mi (2007)
Synthesis and cell activity of novel galactosylated chitosan as a gene carrier.
Baofeng Song (2009)
Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment.
Taek Woong Chung (2002)
Chitosan Based Polyelectrolyte Complexes as Potential Carrier Materials in Drug Delivery Systems
J. Hamman (2010)
Semiquantitative study of the EDC/NHS activation of acid terminal groups at modified porous silicon surfaces.
S. Sam (2010)
The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function.
Zhang-qi Feng (2009)
This paper is referenced by
Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo
Mingrong Cheng (2013)
Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery
A. Hefnawy (2020)
Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo
Mingrong Cheng (2018)
Study on the transfection efficiency of chitosan-based gene vectors modified with poly-l-arginine peptides.
Y. Zhang (2020)
Pegylation effect of chitosan based polyplex on DNA transfection.
W. J. Lin (2015)
Bioenhanced oral curcumin nanoparticles: Role of carbohydrates.
A. D’souza (2016)
Porous Lactose-Modified Chitosan Scaffold for Liver Tissue Engineering: Influence of Galactose Moieties on Cell Attachment and Mechanical Stability
Birong Wang (2016)
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
M. Li (2016)
Bio-production of lactobionic acid: current status, applications and future prospects.
Saúl Alonso (2013)
Fabrication of Chitosan‐18β‐Glycyrrhetinic Acid Modified Titanium Implants with Nanorod Arrays for Suppression of Osteosarcoma Growth and Improvement of Osteoblasts Activity
M. Zhang (2017)
Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
H. Du (2017)
Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
M. Li (2019)
Exploiting the bioengineering versatility of lactobionic acid in targeted nanosystems and biomaterials.
Saúl Alonso (2018)
Glycyrrhetinic acid-modified PEG-PCL copolymeric micelles for the delivery of curcumin
Runliang Feng (2017)
Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA
Q. Zheng (2020)
Dual‐targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma
Mona A. Abdelmoneem (2018)
Doxorubicin-loaded dual-functional hyaluronic acid nanoparticles: Preparation, characterization and antitumor efficacy in vitro and in vivo
Guixiang Tian (2019)
Amphiphilic polysaccharides as building blocks for self‐assembled nanosystems: molecular design and application in cancer and inflammatory diseases
Xiaoye Yang (2018)
Fabrication of chitosan nanoparticles with aggregation-induced emission characteristics and their applications in long-term live cell imaging.
M. Li (2013)